Estimates of radioxenon released from Southern Hemisphere medical isotope production facilities using measured air concentrations and atmospheric transport modeling.

The International Monitoring System (IMS) of the Comprehensive-Nuclear-Test-Ban-Treaty monitors the atmosphere for radioactive xenon leaking from underground nuclear explosions. Emissions from medical isotope production represent a challenging background signal when determining whether measured radioxenon in the atmosphere is associated with a nuclear explosion prohibited by the treaty. The Australian Nuclear Science and Technology Organisation (ANSTO) operates a reactor and medical isotope production facility in Lucas Heights, Australia. This study uses two years of release data from the ANSTO medical isotope production facility and (133)Xe data from three IMS sampling locations to estimate the annual releases of (133)Xe from medical isotope production facilities in Argentina, South Africa, and Indonesia. Atmospheric dilution factors derived from a global atmospheric transport model were used in an optimization scheme to estimate annual release values by facility. The annual releases of about 6.8 × 10(14) Bq from the ANSTO medical isotope production facility are in good agreement with the sampled concentrations at these three IMS sampling locations. Annual release estimates for the facility in South Africa vary from 2.2 × 10(16) to 2.4 × 10(16) Bq, estimates for the facility in Indonesia vary from 9.2 × 10(13) to 3.7 × 10(14) Bq and estimates for the facility in Argentina range from 4.5 × 10(12) to 9.5 × 10(12) Bq.

[1]  M Kalinowski,et al.  Atmospheric transport modelling of time resolved 133Xe emissions from the isotope production facility ANSTO, Australia. , 2013, Journal of environmental radioactivity.

[2]  Gerhard Wotawa,et al.  Xenon-133 and caesium-137 releases into the atmosphere from the Fukushima Dai-ichi nuclear power plant: determination of the source term, atmospheric dispersion, and deposition , 2011 .

[3]  A. Stohl,et al.  Validation of the lagrangian particle dispersion model FLEXPART against large-scale tracer experiment data , 1998 .

[4]  Paul R J Saey,et al.  The influence of radiopharmaceutical isotope production on the global radioxenon background. , 2009, Journal of environmental radioactivity.

[5]  Karin Lindh,et al.  Measurements of radioxenon in ground level air in South Korea following the claimed nuclear test in North Korea on October 9, 2006 , 2009 .

[6]  A. Ringbom,et al.  SAUNA—a system for automatic sampling, processing, and analysis of radioactive xenon , 2003 .

[7]  Kurt Ungar,et al.  Changes in radioxenon observations in Canada and Europe during medical isotope production facility shut down in 2008 , 2009 .

[8]  Martin Kalinowski,et al.  Computation and Analysis of the Global Distribution of the Radioxenon Isotope 133Xe based on Emissions from Nuclear Power Plants and Radioisotope Production Facilities and its Relevance for the Verification of the Nuclear-Test-Ban Treaty , 2010 .

[9]  S. Biegalski,et al.  Source term estimation of radioxenon released from the Fukushima Dai-ichi nuclear reactors using measured air concentrations and atmospheric transport modeling. , 2014, Journal of environmental radioactivity.

[10]  Anders Ringbom,et al.  Environmental Radioxenon Levels in Europe: a Comprehensive Overview , 2010 .

[11]  R. Draxler.  An Overview of the HYSPLIT_4 Modelling System for Trajectories, Dispersion, and Deposition , 1998 .

[12]  Gerhard Wotawa,et al.  The complexity of CTBT verification. Taking noble gas monitoring as an example , 2008, Complex..

[13]  P. Eslinger,et al.  Maximum reasonable radioxenon releases from medical isotope production facilities and their effect on monitoring nuclear explosions. , 2013, Journal of environmental radioactivity.